Search Result
Results for "
bisphosphonates
" in MedChemExpress (MCE) Product Catalog:
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-150167
-
|
|
Bacterial
|
Infection
|
|
TH-Z93, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 90 nM) .
|
-
-
- HY-150168
-
|
|
Bacterial
|
Infection
|
|
TH-Z145, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 210 nM) .
|
-
-
- HY-13777
-
|
Zoledronate; CGP 42446; CGP42446A; ZOL 446
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
|
Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
|
-
-
- HY-13777A
-
|
Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
|
Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .
|
-
-
- HY-B0631
-
|
|
Others
|
Cancer
|
|
Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
|
-
-
- HY-A0213A
-
|
Tiludronic acid disodium
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .
|
-
-
- HY-136829
-
|
|
Others
|
Others
|
|
BPH-675 is a large bisphosphonate inhibitor with long hydrophobic side chains and a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor with an IC50 of 0.71 μM .
|
-
-
- HY-108685
-
|
Alendronic acid monosodium salt
|
Others
|
Metabolic Disease
|
|
Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
|
-
-
- HY-A0213
-
|
Tiludronic acid
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties .
|
-
-
- HY-13777R
-
|
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
|
Zoledronic Acid (Standard) is the analytical standard of Zoledronic Acid. This product is intended for research and analytical applications. Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
|
-
-
- HY-A0213B
-
|
Tiludronic acid disodium hemihydrate
|
Proton Pump
|
Metabolic Disease
|
|
Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H +-ATPase. Antiresorptive and anti-inflammatory properties .
|
-
-
- HY-13777AR
-
|
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
|
Zoledronic acid (monohydrate) (Standard) is the analytical standard of Zoledronic acid (monohydrate). This product is intended for research and analytical applications. Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects .
|
-
-
- HY-13777S
-
|
Zoledronate-d5; CGP 42446-d5; CGP42446A-d5; ZOL 446-d5
|
Bacterial
Apoptosis
Autophagy
Isotope-Labeled Compounds
|
Metabolic Disease
Cancer
|
|
Zoledronic acid-d5 is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
|
-
-
- HY-13777B
-
|
Zoledronate disodium tetrahydrate; CGP 42446 disodium tetrahydrate; CGP42446A disodium tetrahydrate; ZOL 446 disodium tetrahydrate
|
Apoptosis
Autophagy
Bacterial
|
Metabolic Disease
Cancer
|
|
Zoledronic Acid (Zoledronate) disodium tetrahydrate is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid disodium tetrahydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid disodium tetrahydrate also has anti-cancer effects .
|
-
-
- HY-119001
-
|
|
Others
|
Cancer
|
|
BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .
|
-
-
- HY-B0119
-
|
Risedronate sodium
|
Parasite
|
Others
|
|
Risedronic acid (Risedronate) sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption.
|
-
-
- HY-B0515
-
|
BM-210955; RPR-102289A
|
Apoptosis
|
Cancer
|
|
Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
|
-
-
- HY-B0515A
-
|
|
Others
|
Cancer
|
|
Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
|
-
-
- HY-B0515B
-
|
|
Others
|
Metabolic Disease
|
|
Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
|
-
-
- HY-B0730
-
|
|
Bacterial
|
Cancer
|
|
Pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis.
|
-
-
- HY-U00145
-
|
DGBP
|
Ras
|
Inflammation/Immunology
|
|
Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.
|
-
-
- HY-D2133
-
|
Alendronate-Cy5
|
Fluorescent Dye
|
Others
|
|
Cy5-ALN (Alendronate-Cy5) is a fluorescently labeled bisphosphonate probe .
|
-
-
- HY-16011
-
|
3-PEHPC
|
Others
|
Others
|
|
NE 10790, a poor farnesyl pyrophosphate synthase inhibitor, is a phosphonocarboxylate analogue of the potent bisphosphonate risedronate and is a weak antiresorptive agent.
|
-
-
- HY-B0515AS1
-
|
|
Apoptosis
Isotope-Labeled Compounds
|
Cancer
|
|
Ibandronic acid-d3 is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
|
-
-
- HY-118224
-
|
|
Parasite
|
Infection
|
|
BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC50 of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells .
|
-
-
- HY-113933
-
|
|
Others
|
Others
|
|
NE11808 is a potent antiresorptive bisphosphonate that inhibits osteoclast prenylation and effectively inhibits protein prenylation in osteoclasts and suppresses labeling of dye-front end compounds.
|
-
-
- HY-B0515AS
-
|
|
Apoptosis
Isotope-Labeled Compounds
|
Cancer
|
|
Ibandronic Acid-d3 (sodium) is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis[1][2].
|
-
-
- HY-113752
-
|
|
Parasite
|
Infection
|
|
MMV019313 is a potent, non-bisphosphonate inhibitor of farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) with an IC50 of 0.82 µM. MMV019313 has activity against P. falciparum (Parasite) .
|
-
-
- HY-107093
-
|
|
Others
|
Cancer
|
|
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research .
|
-
-
- HY-107093A
-
|
|
Others
|
Cancer
|
|
MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research .
|
-
-
- HY-B0657A
-
|
Clodronate disodium salt
|
Others
|
Inflammation/Immunology
Cancer
|
|
Clodronic acid (Clodronate) disodium salt, a first-generation bisphosphonate, is orally active osteoclastic bone resorption inhibitor. Clodronic acid disodium salt can be used in high bone turnover states, Paget ’s disease and osteolytic bone metastases .
|
-
-
- HY-107093B
-
|
|
Others
|
Cancer
|
|
MBC-11 triethylamine is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential for tumor-induced bone disease (TIBD) research .
|
-
-
- HY-B0657
-
|
Clodronate
|
Others
|
Others
Cancer
|
|
Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
|
-
-
- HY-106431
-
|
Olpadronate; OLP
|
Others
|
Metabolic Disease
Cancer
|
|
Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid also prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .
|
-
-
- HY-B0631S
-
|
|
Isotope-Labeled Compounds
|
Cancer
|
|
Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
|
-
-
- HY-B0302
-
|
Etidronate; HEDPA; HEDP
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-16322
-
|
YM-529
|
P2X Receptor
Apoptosis
|
Cancer
|
|
Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain .
|
-
-
- HY-B0302A
-
|
Etidronate disodium; HEDPA disodium; HEDP disodium
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-16322A
-
|
YM-529 hydrate
|
P2X Receptor
Apoptosis
|
Cancer
|
|
Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain .
|
-
-
- HY-A0213AS
-
|
Tiludronic acid-d5 (sodium)
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
|
-
-
- HY-107794
-
|
Disodium clodronate tetrahydrate
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl - competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain .
|
-
-
- HY-144129
-
|
|
Apoptosis
|
Cancer
|
|
hGGPPS-IN-2 (Compound 16g) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-2 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-2 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .
|
-
-
- HY-144130
-
|
|
Apoptosis
|
Cancer
|
|
hGGPPS-IN-3 (Compound 13h) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-3 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-3 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .
|
-
-
- HY-144128
-
|
|
Apoptosis
|
Cancer
|
|
hGGPPS-IN-1 (Compound 18b) is a potent inhibitor of the human geranylgeranyl pyrophosphate synthase (hGGPPS). hGGPPS-IN-1 is an analogue of C-2-substituted thienopyrimidine-based bisphosphonates (C2-ThP-BPs). hGGPPS-IN-1 induces target-selective apoptosis of multiple myeloma (MM) cells and exhibits antimyeloma activity in vivo .
|
-
-
- HY-16322S
-
|
YM-529-d4
|
Isotope-Labeled Compounds
P2X Receptor
Apoptosis
|
Cancer
|
|
Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].
|
-
-
- HY-108309R
-
|
|
Others
|
Others
|
|
Medronic acid (Standard) is the analytical standard of Medronic acid. This product is intended for research and analytical applications. Medronic acid (Methylenediphosphonic acid) is a methylene-substituted bisphosphonate. Medronic acid has affinity for and adheres to the surface of hydroxyapatite crystals in the bone matrix. Medronic acid can be used in bone imaging, while being complexed with radioisotopes. Due to its strong metal-chelating ability, Medronic acid can also be used as a water treatment chemical .
|
-
-
- HY-108309
-
|
Methylenediphosphonic acid
|
Others
|
Others
|
|
Medronic acid (Methylenediphosphonic acid) is a methylene-substituted bisphosphonate. Medronic acid has an affinity for the surface of hydroxyapatite crystals in the bone matrix and adheres to them. Medronic acid can be used in complex with radioisotopes in bone imaging. Due to its strong metal chelating ability, medronic acid is also used as a water treatment chemical. In addition, medronic acid is used as a solvent additive to improve peak shape and signal of metal-sensitive metabolites in LC/MS analysis .
|
-
-
- HY-B0302AR
-
|
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Etidronic acid (disodium) (Standard) is the analytical standard of Etidronic acid (disodium). This product is intended for research and analytical applications. Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
|
-
-
- HY-101076
-
|
|
Phosphatase
|
Metabolic Disease
|
|
L-690488 is a proagent of L-690330 and is a selective inositol monophosphatase (IMPase) inhibitor. L-690488 has more effective cell penetration than L-690330 .
|
-
-
- HY-B0012
-
|
|
RANKL/RANK
Toll-like Receptor (TLR)
Wnt
β-catenin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
|
-
- HY-B0012B
-
|
|
RANKL/RANK
Toll-like Receptor (TLR)
Wnt
β-catenin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
|
-
- HY-B0012A
-
|
CGP 23339A
|
RANKL/RANK
Toll-like Receptor (TLR)
Wnt
β-catenin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Pamidronate disodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
|
-
- HY-107794R
-
|
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Clodronate (disodium tetrahydrate) (Standard) is the analytical standard of Clodronate (disodium tetrahydrate). This product is intended for research and analytical applications. Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl-competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain .
|
-
- HY-13777C
-
|
CGP 42446 disodium; CGP42446A disodium; ZOL 446 disodium
|
Others
|
Cancer
|
|
Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications.
|
-
- HY-B2097
-
|
YM 175; Bisphonal
|
Farnesyl Transferase
|
Metabolic Disease
|
|
Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
|
-
- HY-B0012AR
-
|
|
RANKL/RANK
Toll-like Receptor (TLR)
Wnt
β-catenin
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Pamidronate disodium (Standard) is the analytical standard of Pamidronate disodium.Pamidronate disodium (Standard), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium (Standard) significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium (Standard) can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
|
-
| Cat. No. |
Product Name |
Type |
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0657
-
|
Clodronate
|
Classification of Application Fields
Disease Research Fields
Cancer
|
Others
|
|
Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0631S
-
|
|
|
Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
|
-
-
- HY-13777S
-
|
|
|
Zoledronic acid-d5 is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .
|
-
-
- HY-B0515AS1
-
|
|
|
Ibandronic acid-d3 is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
|
-
-
- HY-B0515AS
-
|
|
|
Ibandronic Acid-d3 (sodium) is the deuterium labeled Ibandronic acid. Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis[1][2].
|
-
-
- HY-A0213AS
-
|
|
|
Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
|
-
-
- HY-16322S
-
|
|
|
Minodronic acid-d4 is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
